At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 31 enrolled
Drug / intervention
Metformin +1 moredrug
Likely dose
Metformin 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Inflammatory Mediators in Obese Adolescents With Insulin Resistance Following Metformin Treatment: Controlled Randomized Clinical Trial
Hospital Regional de Alta Especialidad del Bajio·interventional·Posted Aug 5, 2011·Updated Apr 27, 2012
In Brief
A Phase 4 clinical trial evaluating Metformin and Placebo for Obesity. Completed, enrolled 31 participants across 2 sites.
Detailed Summary
The purpose of this study is to compare serum concentrations of inflammatory cytokines, interleukin 6 (IL-6), High-sensitivity C-reactive protein (hs-CRP), adiponectin, and tumour necrosis factor alpha (TNFα), before and after three months treatment with metformin in obese adolescents with insulin resistance (IR).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity
CountriesMexico
CollaboratorsHospital Infantil de Mexico Federico Gomez
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2007
Primary CompletionDec 2009
Study CompletionMar 2010
First PostedAug 2011
TodayJul 2026
First PostedAug 5, 2011
Enrollment StartJan 1, 2007
Primary CompletionDec 1, 2009
Study CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 14.9 years ago
Interventions
Metformindrug
Tablet of 500 mg metformin, oral every 12 hours (total metformin dose of 1 g/day) for 3 months.
Placebodrug
Tablet of 500 mg oral placebo every 12 hours for 3 months.